The RTX treatment was also effective in reducing the levels of a cytokine panel integrated by IL‐1β, IL‐6, IFN‐γ and TNF‐α on the lymphocyte population from SLE and RA patients (Figure 4B and 4). This evidence concerns the gene IL6 and systemic lupus erythematosus.